학술논문
Dorsal Root Ganglion Morphometric Changes Under Oxaliplatin Treatment
Original Article
Original Article
Document Type
Clinical report
Author
Source
Clinical Neuroradiology. June 2022, Vol. 32 Issue 2, p547, 10 p.
Subject
Language
English
ISSN
1869-1439
Abstract
Author(s): Leonidas Apostolidis [sup.1], Lars Kowalscheck [sup.1] [sup.2], Tim Frederik Weber [sup.3], Tim Godel [sup.4], Martin Bendszus [sup.4], Hans-Ulrich Kauczor [sup.3], Dirk Jäger [sup.1], Heinz-Peter Schlemmer [sup.2], Philipp Bäumer [sup.2] [...]
Purpose Magnetic resonance neurography (MRN) can detect dorsal root ganglia (DRG) hypertrophy in patients with oxaliplatin-induced peripheral neuropathy (OXIPN) but is difficult to apply in clinical daily practice. Aims of this study were (i) to assess whether DRG volume is reliably measurable by routine computed tomography (CT) scans, (ii) to measure longitudinal changes in DRG during and after oxaliplatin administration and (iii) to assess correlation between DRG morphometry and individual oxaliplatin dose. Methods For comparison of MRN and CT measurements, CT scans of 18 patients from a previous MRN study were analyzed. For longitudinal assessment of DRG size under treatment, 96 patients treated with oxaliplatin between January and December 2014 were enrolled retrospectively. DRG volumetry was performed by analyzing routine CT scans, starting with the last scan before oxaliplatin exposure (t0) and up to four consecutive timepoints after initiation of oxaliplatin therapy (t1-t4) with the following median and ranges in months: 3.1 (0.4-4.9), 6.2 (5.3-7.8), 10.4 (8.2-11.9), and 18.4 (12.8-49.8). Results DRG volume measured in CT showed a moderately strong correlation with MRN (râ¯= 0.51, pâ¯< 0.001) and a strong correlation between two consecutive CTs (râ¯= 0.77, pâ¯< 0.001). DRG volume increased after oxaliplatin administration with a maximum at timepoint t2. Higher cumulative oxaliplatin exposure was associated with significantly higher absolute DRG volumes (pâ¯= 0.005). Treatment discontinuation was associated with a nonsignificant trend towards lower relative DRG volume changes (pâ¯= 0.08). Conclusion CT is a reliable method for continuous DRG morphometry; however, since no standardized assessment of OXIPN was performed in this retrospective study, correlations between DRG size, cumulative oxaliplatin dose and clinical symptoms in future prospective studies are needed to establish DRG size as a potential OXIPN biomarker.
Purpose Magnetic resonance neurography (MRN) can detect dorsal root ganglia (DRG) hypertrophy in patients with oxaliplatin-induced peripheral neuropathy (OXIPN) but is difficult to apply in clinical daily practice. Aims of this study were (i) to assess whether DRG volume is reliably measurable by routine computed tomography (CT) scans, (ii) to measure longitudinal changes in DRG during and after oxaliplatin administration and (iii) to assess correlation between DRG morphometry and individual oxaliplatin dose. Methods For comparison of MRN and CT measurements, CT scans of 18 patients from a previous MRN study were analyzed. For longitudinal assessment of DRG size under treatment, 96 patients treated with oxaliplatin between January and December 2014 were enrolled retrospectively. DRG volumetry was performed by analyzing routine CT scans, starting with the last scan before oxaliplatin exposure (t0) and up to four consecutive timepoints after initiation of oxaliplatin therapy (t1-t4) with the following median and ranges in months: 3.1 (0.4-4.9), 6.2 (5.3-7.8), 10.4 (8.2-11.9), and 18.4 (12.8-49.8). Results DRG volume measured in CT showed a moderately strong correlation with MRN (râ¯= 0.51, pâ¯< 0.001) and a strong correlation between two consecutive CTs (râ¯= 0.77, pâ¯< 0.001). DRG volume increased after oxaliplatin administration with a maximum at timepoint t2. Higher cumulative oxaliplatin exposure was associated with significantly higher absolute DRG volumes (pâ¯= 0.005). Treatment discontinuation was associated with a nonsignificant trend towards lower relative DRG volume changes (pâ¯= 0.08). Conclusion CT is a reliable method for continuous DRG morphometry; however, since no standardized assessment of OXIPN was performed in this retrospective study, correlations between DRG size, cumulative oxaliplatin dose and clinical symptoms in future prospective studies are needed to establish DRG size as a potential OXIPN biomarker.